128 related articles for article (PubMed ID: 7968018)
21. Combination of intravenous iron sucrose and ascorbic acid in hemodialysis patients.
Keven K; Kutlay S; Nergizoglu G; Erturk S
Kidney Int; 2005 Jul; 68(1):411. PubMed ID: 15954940
[No Abstract] [Full Text] [Related]
22. Safety aspects of parenteral iron in patients with end-stage renal disease.
Sunder-Plassmann G; Hörl WH
Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
[TBL] [Abstract][Full Text] [Related]
23. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
24. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
25. Intravenous ferric saccharate as an iron supplement in dialysis patients.
Silverberg DS; Blum M; Peer G; Kaplan E; Iaina A
Nephron; 1996; 72(3):413-7. PubMed ID: 8852489
[TBL] [Abstract][Full Text] [Related]
26. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
[TBL] [Abstract][Full Text] [Related]
27. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
Binkley LS
Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
[No Abstract] [Full Text] [Related]
28. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
Pizzi LT; Bunz TJ; Coyne DW; Goldfarb DS; Singh AK
Kidney Int; 2008 Dec; 74(12):1588-95. PubMed ID: 19034302
[TBL] [Abstract][Full Text] [Related]
29. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
30. Intravenous iron as adjuvant therapy: a two-edged sword?
Cavill I
Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii24-8. PubMed ID: 14607997
[TBL] [Abstract][Full Text] [Related]
31. Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
Coyne DW; Sims A; Bingel B
Nephrol Nurs J; 2008; 35(6):583-7. PubMed ID: 19260610
[TBL] [Abstract][Full Text] [Related]
32. Back to the basics in iron management for the patient receiving epoetin therapy.
Kirlin L
ANNA J; 1991 Aug; 18(4):428. PubMed ID: 1872645
[No Abstract] [Full Text] [Related]
33. Erythropoietin therapy in patients with chronic renal failure.
Pinevich AJ; Petersen J
West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
[TBL] [Abstract][Full Text] [Related]
34. Drug usage evaluation of epoetin in chronic renal failure.
Mason NA; Iacobellis DP
Hosp Formul; 1992 Sep; 27(9):928-32, 937-8. PubMed ID: 10121421
[TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
36. Approaches to inverse-probability-of-treatment--weighted estimation with concurrent treatments.
Ellis AR; Brookhart MA
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S51-6. PubMed ID: 23849154
[TBL] [Abstract][Full Text] [Related]
37. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
Adhikary L; Acharya S
JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
[TBL] [Abstract][Full Text] [Related]
39. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
Krafft A; Breymann C
J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
Moran LJ; Carey P; Johnson CA
Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
